 Bicalutamide, an androgen receptor AR antagonist, is frequently used as the first secondary hormonal therapy in combination with another established agent LHRH: luteinizing hormone-releasing hormone agonistantagonist to treat CRPC. A series of studies have shown that RAD001 through inhibition of mammalian target of rapamycin mTOR pathway has antitumor and anti-angiogenic activities. The hypothesis is that the combination of an antiandrogen and mTOR inhibitor would have additive and clinically significant effects in CRPC. 